Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 24;7(2):246-250.
doi: 10.1182/bloodadvances.2022007336.

Characteristics of VITT antibodies in patients vaccinated with Ad26.COV2.S

Affiliations

Characteristics of VITT antibodies in patients vaccinated with Ad26.COV2.S

Angela Huynh et al. Blood Adv. .

Erratum in

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Alanine scanning mutagenesis was used to map epitopes of amino acids on PF4 that are critical for binding antibodies from patients 1, 2, and 3. (A) Patient 1, (B) patient 2, and (C) patient 3 showed that there is a binding region (red) that aligns with (D) the previously described VITT binding region for ChAdOx1 nCoV-19 (AstraZeneca) vaccination (red, R22, H23, E28, K46, N47, K50, K62, K66) and within (E) the heparin-binding region on PF4 (purple). All 3 patients also have additional amino acids that are important in binding that correspond to the PF4 binding site of typical HIT (blue). However, patient 2 only had 3 additional amino acids outside the typical VITT binding site. Antibody epitopes usually comprise 5 to 8 amino acids; therefore, although important binding amino acids were found in the typical HIT site, there are not enough amino acids to constitute a full epitope. Because patient antibodies are polyclonal, it is possible that the pool of antibodies that binds outside the typical VITT site has either a lower titer or a weaker affinity that cannot be differentiated in the assay. Images are modified from Protein Data Bank file 1RHP.

References

    1. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092–2101. - PMC - PubMed
    1. Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384(22):2124–2130. - PMC - PubMed
    1. Scully M, Singh D, Lown R, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384(23):2202–2211. - PMC - PubMed
    1. See I, Su JR, Lale A, et al. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021. JAMA. 2021;325(24):2448–2456. - PMC - PubMed
    1. Huynh A, Kelton JG, Arnold DM, Daka M, Nazy I. Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia. Nature. 2021;596(7873):565–569. - PubMed

Publication types

Grants and funding